Joseph Rubinfeld Net Worth

What's Joseph Rubinfeld's mailing address?

Joseph's mailing address filed with the SEC is C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN, CA, 94568.

Insiders trading at LadRx Corp

Over the last 21 years, insiders at LadRx Corp have traded over $0 worth of LadRx Corp stock and bought 3,710,406 units worth $8,711,088 . The most active insiders traders include Steven A Kriegsman, Scott Bradford Patterson und Max Link. On average, LadRx Corp executives and independent directors trade stock every 177 days with the average trade being worth of $22,531. The most recent stock trade was executed by Earl W Brien on 14 August 2020, trading 150,000 units of CYTR stock currently worth $39,000.

What does LadRx Corp do?

LadRx Corp executives and stock owners

LadRx Corp executives and other stock owners filed with the SEC include:

• Steven Kriegsman,
  Chairman of the Board, Chief Executive Officer
• Steven A. Kriegsman,
  Chief Exec. Officer
• John Caloz,
  Chief Financial Officer, Chief Accounting Officer, IR Contact Officer
• John Y. Caloz,
  CFO, Treasurer & Sr. VP
• Louis Ignarro,
  Independent Director
• Joel Caldwell,
  Director
• Earl Brien,
  Director
• Dr. Felix Kratz Ph.D.,
  Sr. VP, Drug Devel.
• Cristina Newman,
  Corp. Sec.
• Terri Stevens,
  Chief Bus. Officer
• Molly Painter,
  Pres of USA and Head of Launch & Commercial Operations
• Molly Carey Poarch,
  Global & U.S. Head of Corp. Communications
• Jennifer K. Simpson,
  Director
• Anita J Chawla,
  Director
• Daniel J Levitt,
  Chief Medical Officer
• Joseph Rubinfeld,
  Director
• Olivia C Ware,
  Chief Commercial Officer
• Douglas Scott Wieland,
  Sr. VP - Drug Development
• Felix Kratz,
  Vice President Drug Discovery
• Herbert H Jr Mcdade,
  
• Alexander L Cappello,
  Director
• Raymond C Jr Carnahan,
  
• Ben Levin,
  Gen.Cnsl/VP Legal Affairs/Secy
• Eric Jay Selter,
  Director
• Cheryl Cohen,
  Director
• Scott Bradford Patterson,
  10% owner
• Marvin R Selter,
  Director
• Richard J Wennekamp,
  Director
• Max Link,
  Director
• David Scott Geyer,
  Sr. V.P. of Manufacturing
• Mitchell K Fogelman,
  Chief Financial Officer
• Jack R Barber,
  Sr VP - Drug Development
• Shi Chung Ng,
  Sr. VP Research & Development
• Matt Natalizio,
  Chief Financial Officer
• Mark Tepper,
  Vice President
• Stephen Snowdy,
  Chief Executive Officer